Back to results
US 10,039,820 B2Granted
West nile virus vaccine comprising WN-80E recombinant subunit protein
AssigneeHawaii Biotech, Inc.
InventorsBeth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
Life of this patent
Estimating the term…
Abstract
A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
Claims7
A vaccine comprising:
- an effective amount of purified protein as set forth in SEQ ID NO:1 and an effective amount of aluminum hydroxide adjuvant, formulated in dosage form of 15-50 ug per dose, and wherein the vaccine induces the production of neutralizing antibodies for West Nile virus in human subjects.
Dependencies are inferred from the claim text.